DURECT Corporation (DRRX): Price and Financial Metrics


DURECT Corporation (DRRX)

Today's Latest Price: $1.77 USD

0.12 (7.27%)

Updated Sep 25 4:00pm

Add DRRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DRRX Stock Summary

  • DRRX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 189.11 -- higher than 83.62% of US-listed equities with positive expected earnings growth.
  • Price to trailing twelve month operating cash flow for DRRX is currently 315.29, higher than 98.97% of US stocks with positive operating cash flow.
  • Revenue growth over the past 12 months for Durect Corp comes in at 153.13%, a number that bests 96.25% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Durect Corp, a group of peers worth examining would be EXEL, ESPR, TNAV, CRUS, and SMCI.
  • DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.
DRRX Daily Price Range
DRRX 52-Week Price Range

DRRX Stock Price Chart Technical Analysis Charts


DRRX Price/Volume Stats

Current price $1.77 52-week high $3.95
Prev. close $1.65 52-week low $0.95
Day low $1.65 Volume 893,313
Day high $1.80 Avg. volume 1,437,713
50-day MA $1.98 Dividend yield N/A
200-day MA $2.08 Market Cap 355.02M

DURECT Corporation (DRRX) Company Bio


DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.

DRRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$1.77$0.02 -99%

We started the process of determining a valid price forecast for Durect Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Durect Corp ranked in the 4th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Durect Corp, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 0.23; that's higher than only 24.31% of US stocks in the Healthcare sector that have positive free cash flow.
  • Durect Corp's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-99%
1%-99%
2%-99%
3%-98%
4%-98%
5%-98%

Want more companies with a valuation profile/forecast similar to that of Durect Corp? See DRAD, AGHC, ALC, AMRN, and FGEN.


DRRX Latest News Stream


Event/Time News Detail
Loading, please wait...

DRRX Latest Social Stream


Loading social stream, please wait...

View Full DRRX Social Stream

Latest DRRX News From Around the Web

Below are the latest news stories about Durect Corp that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury

DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The company plans to enroll approximately 80 patients in multiple study sites across the U.S.

Yahoo | September 23, 2020

DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM)

DURECT Corporation (NASDAQ: DRRX) today announced the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe alcoholic hepatitis (AH) patients.

Yahoo | September 22, 2020

DURECT Corporation to Participate in September Virtual Investor Conferences

DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the HC Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Yahoo | September 10, 2020

Durect (DRRX) Investor Presentation - Slideshow

The following slide deck was published by DURECT Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | August 28, 2020

DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital International Liver Congress (EASL)

DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress™ 2020 (EASL), taking place on August 27-29. DUR-928 was well tolerated at all doses tested in 19 AH patients, including 12 severe AH patients. These PK data, together with other available information for the drug, have been used to inform dose selection in the Company's upcoming Phase 2b study of DUR-298 in AH, planned to begin in the second half of 2020.

Yahoo | August 27, 2020

Read More 'DRRX' Stories Here

DRRX Price Returns

1-mo -2.75%
3-mo -29.20%
6-mo 14.19%
1-year -10.61%
3-year 0.57%
5-year -4.84%
YTD -53.42%
2019 691.67%
2018 -47.83%
2017 -31.34%
2016 -39.37%
2015 179.75%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7354 seconds.